Upside case
Bull case
$124+104.8%
DXCM would need investors to value it at roughly 50x earnings — about 25x more generous than today's 24x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated May 1, 2026
DexCom, Inc. (DXCM) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
52
analysts
42 bullish · 2 bearish · 52 covering DXCM
Strong Buy
1
Buy
41
Hold
8
Sell
2
Strong Sell
0
Consensus Target
$81
+34.0% vs today
Scenario Range
— – $124
Model bear to bull value window
Coverage
52
Published analyst ratings
Valuation Context
24.2x
Forward P/E · Market cap $23.3B
DXCM price targets
Three scenarios for where DXCM stock could go
Current
~$60
Confidence
69 / 100
Updated
May 1, 2026
Where we are now
Current · $60
Base
$95
Bull
$124
Market caseClosest to today
Base case
$95+57.1%
At 38x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
—
The bear case reflects a scenario where earnings shortfalls or multiple compression combine to materially reduce the stock from its current level.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
DexCom, Inc.
DXCM · NASDAQHealthcareMedical - DevicesDecember year-end
DexCom is a medical device company that designs and sells continuous glucose monitoring systems for people with diabetes. It generates revenue primarily from sensor sales — which account for roughly 85% of total revenue — with the remainder coming from transmitters and software services. The company's competitive advantage lies in its highly accurate, real-time CGM technology and its established ecosystem of integrated diabetes management solutions.
Market Cap
$23.3B
Revenue TTM
$4.8B
Net Income TTM
$930M
Net Margin
19.3%
DXCM Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
83%Exceptional
12 quarters tracked
Revenue Beat Rate
92%Exceptional
vs consensus estimates
Avg EPS Surprise
+14.3%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 4 of 4Q3 2025
EPS
$0.48/$0.44
Revenue
$1.2B/$1.1B
Q4 2025
EPS
$0.61/$0.58
Revenue
$1.2B/$1.2B
Q1 2026
EPS
$0.68/$0.65
Revenue
$1.3B/$1.2B
Q2 2026
EPS
$0.56/$0.47
Revenue
$1.2B/$1.2B
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $0.48/$0.44 | +8.2% | $1.2B/$1.1B | +2.9% |
| Q4 2025 | $0.61/$0.58 | +5.9% | $1.2B/$1.2B | +2.2% |
| Q1 2026 | $0.68/$0.65 | +4.6% | $1.3B/$1.2B | +0.9% |
| Q2 2026 | $0.56/$0.47 | +19.1% | $1.2B/$1.2B | +1.5% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$5.4B
+12.9% YoY
FY2
$6.3B
+15.9% YoY
EPS Outlook
FY1
$2.70
+14.3% YoY
FY2
$3.28
+21.5% YoY
Trailing FCF (TTM)$1.4B
FCF Margin: 29.7%
Next Earnings
—
Expected EPS
—
Expected Revenue
—
DXCM beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
DXCM Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $1.3B
Product Mix
Latest annual revenue by segment or product family
Segment breakdown not available for this company.
Geographic Mix
Latest annual revenue by reported region
Non-US
100.0%
+33.1% YoY
Tap, hover, or focus a slice to inspect segment detail.
Non-US is the largest reported region at 100.0%, up 33.1% YoY.
DXCM Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Significantly Undervalued
Fair value est. $127 — implies +107.4% from today's price.
Upside to Fair Value
107.4%
potential upside
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
DXCM
28.9x
vs
S&P 500
25.2x
+14% premium
vs Healthcare Trailing P/E
DXCM
28.9x
vs
Healthcare
22.1x
+30% premium
vs DXCM 5Y Avg P/E
Today
28.9x
vs
5Y Average
80.9x
64% discount
Forward PE
24.2x
S&P 500
19.1x
+27%
Healthcare
19.0x
+27%
5Y Avg
—
—
Trailing PE
28.9x
S&P 500
25.2x
+14%
Healthcare
22.1x
+30%
5Y Avg
80.9x
-64%
PEG Ratio
2.76x
S&P 500
1.75x
+58%
Healthcare
1.52x
+81%
5Y Avg
—
—
EV/EBITDA
20.4x
S&P 500
15.3x
+34%
Healthcare
14.1x
+44%
5Y Avg
56.6x
-64%
Price/FCF
21.6x
S&P 500
21.3x
+1%
Healthcare
18.7x
+16%
5Y Avg
84.5x
-74%
Price/Sales
5.0x
S&P 500
3.1x
+59%
Healthcare
2.8x
+75%
5Y Avg
13.7x
-64%
Dividend Yield
—
S&P 500
1.88%
—
Healthcare
1.40%
—
5Y Avg
—
—
| Metric | DXCM | S&P 500 | Healthcare | 5Y Avg DXCM |
|---|---|---|---|---|
| Forward PE | 24.2x | 19.1x+27% | 19.0x+27% | — |
| Trailing PE | 28.9x | 25.2x+14% | 22.1x+30% | 80.9x-64% |
| PEG Ratio | 2.76x | 1.75x+58% | 1.52x+81% | — |
| EV/EBITDA | 20.4x | 15.3x+34% | 14.1x+44% | 56.6x-64% |
| Price/FCF | 21.6x | 21.3x | 18.7x+16% | 84.5x-74% |
| Price/Sales | 5.0x | 3.1x+59% | 2.8x+75% | 13.7x-64% |
| Dividend Yield | — | 1.88% | 1.40% | — |
DXCM trades above S&P 500 benchmarks on 5 of 6 measured multiples — commands a broad premium across most valuation dimensions.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolDXCM Financial Health
Verdict
Exceptional
DXCM generates $1.4B in free cash flow at a 29.7% margin — 18.7% ROIC signals a durable competitive advantage · returns 2.1% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$4.8B
Revenue Growth
TTM vs prior year
+16.2%
Gross Margin
Gross profit as a share of revenue
61.8%
Operating Margin
Operating income divided by revenue
21.4%
Net Margin
Net income divided by revenue
19.3%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$2.36
Free Cash Flow (TTM)
Cash generation after capex
$1.4B
FCF Margin
FCF as share of revenue — the primary cash quality signal
29.7%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
18.7%
ROA
Return on assets, trailing twelve months
13.4%
Cash & Equivalents
Liquid assets on the balance sheet
$918M
Net Debt
Total debt minus cash
$472M
Debt Serviceability
Net debt as a multiple of annual free cash flow
0.3× FCF
~0.3 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
33.8%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
2.1%
Dividend
—
Buyback
2.1%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$500M
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Declining as buybacks retire shares
386M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageDXCM Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 29, 2026
High Risk
Stock Price Volatility
The market price of DXCM stock is subject to significant fluctuations influenced by factors beyond the company's control, such as analyst coverage and general economic conditions. This volatility can lead to unpredictable financial performance and investor sentiment.
High Risk
Valuation Concerns
Dexcom's premium valuation leaves little room for error; if adoption or reimbursement growth slows, the stock's premium multiple could limit returns. This could significantly impact investor confidence and stock performance.
High Risk
Regulatory Environment
Operating within a regulated industry, Dexcom faces risks from potential changes in regulations or adverse regulatory actions. Such changes could materially impact its business operations and financial stability.
High Risk
Competition
The continuous glucose monitoring (CGM) market is increasingly competitive, with significant investments from rivals like Abbott. Any pricing pressure or slower-than-expected adoption could negatively affect Dexcom's market position and financial results.
Medium
Debt and Financing
Dexcom's debt-to-equity ratio of 0.45 indicates some financial leverage that could pose risks during an economic downturn. While manageable, this leverage could impact the company's financial flexibility.
Medium
Reimbursement Rates
Dexcom must manage the risk of potential cuts to reimbursement rates, which could adversely affect revenue and profit margins. Changes in reimbursement policies can significantly impact the company's financial outlook.
Medium
Market Saturation
There's a belief that the total addressable market for CGMs is already highly penetrated, which could limit future growth opportunities. This saturation may lead to increased competition and pricing pressures.
Lower
Execution Risks
Potential challenges exist in the growing international market, including execution risks and the possibility of trading at a discount to peers. These factors could hinder Dexcom's ability to capitalize on international growth opportunities.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why DXCM Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 29, 2026
Market Leadership and Growth
DexCom is a global leader in the continuous glucose monitoring (CGM) market, which is experiencing significant growth due to the increasing prevalence of diabetes worldwide. The company's innovative products, such as the G7 sensor and the over-the-counter Stelo product, are expected to drive user growth.
Expanding Addressable Market
DexCom is strategically targeting underserved segments of the diabetes market, including patients with Type 2 diabetes who are not on intensive insulin therapy. Expanded insurance coverage for these patient groups is opening up a significantly larger market, and the company aims to more than triple its total addressable market.
Strong Financial Performance
DexCom has demonstrated consistent, double-digit revenue growth, with recent quarters showing reaccelerating growth. The company operates a high-margin, recurring revenue model driven by disposable sensor sales, and analysts project continued strong earnings growth in the coming years.
Analyst Confidence
A significant majority of Wall Street analysts have a 'Buy' or 'Strong Buy' rating on DXCM stock, with a consensus price target suggesting considerable upside potential. Analysts highlight the company's strong fundamentals, innovative pipeline, and market position.
Product Innovation and Ecosystem
DexCom continues to invest in R&D, focusing on product enhancements and strong ecosystem integration with other digital health tools and insulin pumps. This ongoing innovation is expected to bolster its competitive advantage in the market.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
DXCM Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$60.36
52W Range Position
17%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$54.11
+11.6% from the low
52-Week High
$89.98
-32.9% from the high
1 Month
-4.51%
3 Month
-13.73%
YTD
-9.3%
1 Year
-26.0%
3Y CAGR
-20.5%
5Y CAGR
-7.5%
10Y CAGR
+14.7%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
DXCM vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
24.2x
vs 15.7x median
+54% above peer median
Revenue Growth
+12.9%
vs +9.3% median
+38% above peer median
Net Margin
19.3%
vs 10.4% median
+85% above peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
DXC DXCM DexCom, Inc. | $23.3B | 24.2x | +12.9% | 19.3% | Buy | +34.0% |
ABT ABT Abbott Laboratories | $150.0B | 15.7x | +9.3% | 31.9% | Buy | +49.2% |
POD PODD Insulet Corporation | $10.6B | 23.8x | +29.8% | 10.4% | Buy | +124.3% |
TND TNDM Tandem Diabetes Care, Inc. | $1.2B | — | +7.9% | -20.2% | Buy | +75.4% |
NVC NVCR NovoCure Limited | $1.9B | — | +6.5% | -25.7% | Buy | +103.1% |
INV INVA Innoviva, Inc. | $1.9B | 11.8x | +11.8% | 118.9% | Buy | +67.3% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
DXCM Dividend and Capital Return
DXCM returns 2.2% annually — null% through dividends and 2.2% through buybacks.
Dividend UnknownFCF Unknown
Total Shareholder Yield
2.2%
Dividend + buyback return per year
Buyback Yield
2.2%
Dividend Yield
—
Payout Ratio
—
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.00
Growth Streak
Consecutive years of dividend increases
0Y
3Y Div CAGR
—
5Y Div CAGR
—
Ex-Dividend Date
—
Payment Cadence
—
0 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$500M
Estimated Shares Retired
8M
Approx. Share Reduction
2.1%
Shares Outstanding
Current diluted share count from the screening snapshot
386M
At 2.1%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
FAQ
7 questionsDXCM Investor Questions
Common questions answered from live analyst data and company financials.
01Is DexCom, Inc. (DXCM) stock a buy or sell in 2026?
DexCom, Inc. (DXCM) is rated Buy by Wall Street analysts as of 2026. Of 52 analysts covering the stock, 42 rate it Buy or Strong Buy, 8 rate it Hold, and 2 rate it Sell or Strong Sell. The consensus 12-month price target is $81, implying +34.0% from the current price of $60.
02What is the DXCM stock price target for 2026?
The Wall Street consensus price target for DXCM is $81 based on 52 analyst estimates. The high-end target is $100 (+65.7% from today), and the low-end target is $67 (+11.0%). The base case model target is $95.
03Is DexCom, Inc. (DXCM) stock overvalued in 2026?
DXCM trades at 24.2x times forward earnings. The stock's valuation is broadly in line with the broader market. Based on current multiples versus the peer group, the relative model signals significantly undervalued. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for DexCom, Inc. (DXCM) stock in 2026?
The primary risks for DXCM in 2026 are: (1) Stock Price Volatility — The market price of DXCM stock is subject to significant fluctuations influenced by factors beyond the company's control, such as analyst coverage and general economic conditions. (2) Valuation Concerns — Dexcom's premium valuation leaves little room for error; if adoption or reimbursement growth slows, the stock's premium multiple could limit returns. (3) Regulatory Environment — Operating within a regulated industry, Dexcom faces risks from potential changes in regulations or adverse regulatory actions. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is DexCom, Inc.'s revenue and earnings forecast?
Analyst consensus estimates DXCM will report consensus revenue of $5.4B (+12.9% year-over-year) and EPS of $2.70 (+14.3% year-over-year) for the upcoming fiscal year. The following year, analysts project $6.3B in revenue.
06When does DexCom, Inc. (DXCM) report its next earnings?
A confirmed upcoming earnings date for DXCM is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
07How much free cash flow does DexCom, Inc. generate?
DexCom, Inc. (DXCM) generated $1.4B in free cash flow over the trailing twelve months — a free cash flow margin of 29.7%. DXCM returns capital to shareholders through and share repurchases ($500M TTM).